Oppenheimer reiterates Outperform rating on Nyxoah stock with $13 target

Nyxoah SA reported Q2 2025 revenue of €1.3 million, meeting consensus but missing Oppenheimer's estimate, while maintaining strong liquidity despite rapid cash burn. The company secured full FDA approval for its Genio device for moderate-to-severe Obstructive Sleep Apnea and is pursuing label expansion, leading Oppenheimer and Stifel to reiterate Outperform/Buy ratings with $12-$13 price targets. However, the hypoglossal nerve stimulation market faces intensifying competition with Genio's commercialization and LIVN's anticipated 2026 entry, alongside observed slowing utilization growth in existing unilateral HGNS therapies, as Nyxoah strategically targets high-volume U.S. centers for its launch.

Analysis

Nyxoah SA (NASDAQ:NYXH) has secured a pivotal catalyst with the full FDA approval for its Genio device, targeting the moderate-to-severe Obstructive Sleep Apnea market. This regulatory success is the primary driver behind reaffirmed Outperform and Buy ratings from Oppenheimer and Stifel, with price targets set at $13.00 and $12.00 respectively, who view the approval as more significant than the recent financial performance. The company's second-quarter 2025 revenue of €1.3 million met consensus estimates but missed Oppenheimer's €1.5 million forecast. While the company maintains strong liquidity, indicated by a current ratio of 3.59, it is concurrently experiencing rapid cash burn, a critical factor to monitor during its commercialization phase. Looking ahead, Nyxoah is pursuing a label expansion for Complete Concentric Collapse (CCC), having closed its ACCESS trial enrollment early due to confidence in the existing data. However, the company faces a challenging competitive landscape, with field checks suggesting slowing growth in existing unilateral hypoglossal nerve stimulation (HGNS) therapies and the anticipated market entry of competitor LivaNova (LIVN) in late 2026. Nyxoah's commercial strategy is highly focused, targeting approximately 300 high-volume U.S. centers that constitute 75% of the industry's procedure volume.

Key Decisions for Investors

• Investors should closely monitor the initial commercial uptake and revenue ramp of the Genio device, as successful execution of the focused launch strategy in high-volume centers is the key near-term valuation driver.
• Given the company's rapid cash burn, it is crucial to scrutinize future quarterly cash flow statements and management's capital allocation strategy to assess its financial runway through the commercial launch period.
• The intensifying competitive environment, including slowing growth in the broader HGNS market and a new entrant expected in 2026, warrants close observation of market share data and pricing dynamics as potential risks to Nyxoah's growth projections.